ARCH Venture Partners X, L.P. — SEC insider filings

SEC reporting owner CIK 1782583. 12 insider filings on record with FilingPulse; latest filed 2026-11-02.

Transaction summary — filings shown

Covers all 12 filings on record, filed 2021-02-10 to 2026-11-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Prime Medicine, Inc. (PRME)10% owner34 legs · 7,030,300 sh · $43,599,990—6
Neumora Therapeutics, Inc. (NMRA)10% owner32 legs · 3,415,700 sh · $30,499,977—12
Aspen Neuroscience, Inc. (ASPE)10% owner23 legs · 1,333,333 sh · $19,999,995—18
Sana Biotechnology, Inc. (SANA)10% owner23 legs · 1,818,181 sh · $9,999,996—14
Erasca, Inc. (ERAS)10% owner1——8
Verve Therapeutics, Inc. (VERV)10% owner1——6

Insider filings — ARCH Venture Partners X, L.P.

FiledFormIssuerReported transactionsSource
2026-11-024Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 66,666 @ $15 · Conversion (C): 187,182 · Conversion (C): 298,258 · Conversion (C): 286,304 · Conversion (C): 295,490 · Conversion (C): 259,948 · +15 moreEDGAR
2026-10-293Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN, NELSEN ROBERT
Holdings only — no transactions reportedEDGAR
2025-10-294Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P.
Purchase (P): 1,915,700 @ $2.61EDGAR
2025-08-014Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Purchase (P): 3,030,300 @ $3.30EDGAR
2024-02-204Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Purchase (P): 3,200,000 @ $6.25EDGAR
2024-02-124Sana Biotechnology, Inc. (SANA)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC
Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50EDGAR
2023-12-124Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P.
Other (J): 703,061 · Other (J): 1,176,593EDGAR
2023-09-204Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P.
Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · Purchase (P): 1,500,000 @ $17 · +5 moreEDGAR
2022-10-264Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Conversion (C): 5,728,297 · Conversion (C): 5,728,297 · Purchase (P): 400,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 16,666,667 (derivative) @ $0 · Conversion (C): 16,666,664 (derivative) @ $0 · +2 moreEDGAR
2021-07-204Erasca, Inc. (ERAS)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., NELSEN ROBERT, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Conversion (C): 5,527,777 · Conversion (C): 5,527,777 · Conversion (C): 2,100,000 (derivative) · Conversion (C): 2,100,000 (derivative) · Conversion (C): 3,400,000 (derivative) · Conversion (C): 1,133,333 (derivative) · +2 moreEDGAR
2021-06-234Verve Therapeutics, Inc. (VERV)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN
Conversion (C): 1,254,404 · Conversion (C): 1,254,405 · Conversion (C): 7,107,024 (derivative) · Conversion (C): 7,107,023 (derivative) · Conversion (C): 4,508,144 (derivative) · Conversion (C): 4,508,146 (derivative)EDGAR
2021-02-104Sana Biotechnology, Inc. (SANA)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC
Conversion (C): 10,156,250 · Conversion (C): 10,156,250 · Conversion (C): 11,718,750 · Conversion (C): 11,718,750 · Conversion (C): 3,687,500 (derivative) @ $0 · Conversion (C): 3,687,500 (derivative) @ $0 · +8 moreEDGAR

FilingPulse's Form 4 archive currently extends back to 2021-02-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1782583 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs